EBS Quote, Financials, Valuation and Earnings

Cara Therapeutics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -527.77%. Emergent BioSolutions's return on equity of -35.42% beat Cara Therapeutics's return on equity of -374.56%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 136.43%. On the other hand Cara Therapeutics has an analysts' consensus of $12.00 which suggests that it could grow by 133.92%. Given that Emergent BioSolutions has higher upside potential than Cara Therapeutics, analysts believe Emergent BioSolutions is more attractive than Cara Therapeutics.

Emergent BioSolutions has a beta of 1.799, which suggesting that the stock is 79.924% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.499, suggesting its less volatile than the S&P 500 by 50.057%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Cara Therapeutics quarterly revenues of $1.5M. Emergent BioSolutions's net income of -$31.3M is lower than Cara Therapeutics's net income of -$7.7M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.30x versus 3.28x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

MAIA Biotechnology has a net margin of -16.54% compared to Emergent BioSolutions's net margin of --. Emergent BioSolutions's return on equity of -35.42% beat MAIA Biotechnology's return on equity of --.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 136.43%. On the other hand MAIA Biotechnology has an analysts' consensus of $12.63 which suggests that it could grow by 714.52%. Given that MAIA Biotechnology has higher upside potential than Emergent BioSolutions, analysts believe MAIA Biotechnology is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 1.799, which suggesting that the stock is 79.924% more volatile than S&P 500. In comparison MAIA Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MAIA Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. MAIA Biotechnology pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than MAIA Biotechnology quarterly revenues of --. Emergent BioSolutions's net income of -$31.3M is lower than MAIA Biotechnology's net income of -$2.7M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while MAIA Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.30x versus -- for MAIA Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of 21.57%. Emergent BioSolutions's return on equity of -35.42% beat TG Therapeutics's return on equity of 12.81%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 136.43%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 4.88%. Given that Emergent BioSolutions has higher upside potential than TG Therapeutics, analysts believe Emergent BioSolutions is more attractive than TG Therapeutics.

Emergent BioSolutions has a beta of 1.799, which suggesting that the stock is 79.924% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than TG Therapeutics quarterly revenues of $108.2M. Emergent BioSolutions's net income of -$31.3M is lower than TG Therapeutics's net income of $23.3M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 291.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.30x versus 19.45x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Traws Pharma has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -14868.42%. Emergent BioSolutions's return on equity of -35.42% beat Traws Pharma's return on equity of -124.39%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 136.43%. On the other hand Traws Pharma has an analysts' consensus of -- which suggests that it could grow by 118.98%. Given that Emergent BioSolutions has higher upside potential than Traws Pharma, analysts believe Emergent BioSolutions is more attractive than Traws Pharma.

Emergent BioSolutions has a beta of 1.799, which suggesting that the stock is 79.924% more volatile than S&P 500. In comparison Traws Pharma has a beta of 1.422, suggesting its more volatile than the S&P 500 by 42.177%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Traws Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Traws Pharma pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Traws Pharma quarterly revenues of $57K. Emergent BioSolutions's net income of -$31.3M is lower than Traws Pharma's net income of -$8.5M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Traws Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.30x versus 11.08x for Traws Pharma. Usually stocks with elevated PS ratios are considered overvalued.